Cargando…

Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype

The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Caggiari, Laura, Miolo, Gianmaria, Buonadonna, Angela, Basile, Debora, Santeufemia, Davide A., Cossu, Antonio, Palmieri, Giuseppe, De Zorzi, Mariangela, Fornasarig, Mara, Alessandrini, Lara, Canzonieri, Vincenzo, Lo Re, Giovanni, Puglisi, Fabio, Steffan, Agostino, Cannizzaro, Renato, De Re, Valli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795997/
https://www.ncbi.nlm.nih.gov/pubmed/29295527
http://dx.doi.org/10.3390/ijms19010047
Descripción
Sumario:The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed. Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the HER2 and the E-cadherin interactions in vivo and in response to treatments.